ECONOMICS OF A VIRTUAL CARE MODEL FOR DIAGNOSIS AND TREATMENT OF SLEEP APNEA IN GERMANY: RESULTS FROM A COST-CONSEQUENCE ANALYSIS

被引：0
|
作者：
Braun, M. [1 ]
Janott, C. [2 ]
Schoebel, C. [3 ]
Heiser, C. [4 ]
Sommer, U. J. [5 ]
机构：
[1] Univ Hosp Essen, Essen, NW, Germany
[2] Diametos GmbH, Potsdam, Germany
[3] Univ Hosp Duisburg Essen, Essen, NW, Germany
[4] Tech Univ Munich, Munich, Germany
[5] HNO ZENTRUM Mangfall Inn, Bad Aibling, BY, Germany
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD100
引用
收藏
页码：S344 / S344
页数：1
相关论文
共 46 条
  • [1] Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia
    Gil-Rojas, Yaneth
    Lasalvia, Pieralessandro
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 609 - 615
  • [2] COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN GERMANY
    von Depka, M.
    Salama, A.
    Perrin, A.
    Oelze, I.
    Chulikavit, M.
    Kunz, E.
    Kutikova, L.
    Thalheimer, M.
    HAEMATOLOGICA, 2012, 97 : 427 - 427
  • [3] A COST-CONSEQUENCE ANALYSIS OF DIFFERENT PROTEASE INHIBITORS SCHEMES FOR HIV TREATMENT FROM THE COLOMBIAN HEALTH CARE SYSTEM PERSPECTIVE
    Rueda, J. D.
    Ariza, J. G.
    VALUE IN HEALTH, 2013, 16 (07) : A713 - A713
  • [4] A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project
    Wimo, Anders
    Belger, Mark
    Bon, Jaka
    Jessen, Frank
    Dumas, Annette
    Kramberger, Milica G.
    Jamilis, Laura
    Johansson, Gunilla
    Rodrigo Salas, Adrian
    Gomez, Octavio Rodriguez
    Sannemann, Lena
    Stoekenbroek, Malou
    Gurruchaga Telleria, Miren
    Valero, Sergi
    Vermunt, Lisa
    Waterink, Lisa
    Winblad, Bengt
    Jelle Visser, Peter
    Zwan, Marissa
    Boada, Merce
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 83 (03) : 1149 - 1159
  • [5] COST-CONSEQUENCE ANALYSIS OF FREMANEZUMAB TREATMENT IN PATIENTS WITH MIGRAINE AND COMORBID MAJOR DEPRESSIVE DISORDER IN THE UK USING RESULTS FROM THE UNITE STUDY
    Mitsikostas, D.
    Guevara, Morel A. E.
    Ramirez-Campos, V
    Driessen, M. T.
    Jain, R.
    VALUE IN HEALTH, 2024, 27 (12) : S124 - S124
  • [6] A cost-consequence analysis of treatment of vesicoureteral reflux (VUR): Which children benefit from antimicrobial prophylaxis?
    Shaikh, N.
    Rajakumar, V.
    Gorski, J.
    Ivanova, A.
    Gravens-Muller, L.
    Pohl, H.
    Matthews, R.
    Hoberman, A.
    PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1759 - 1759
  • [7] Point of Care Nucleic Acid Testing for Influenza-Like Illness: A Cost-Consequence Analysis for High-Risk Patients in Primary Care in Germany
    Pohlmann, Johannes
    Joecker, Anika
    Wittki, Tanja
    Brown, Tray
    Pollock, Richard F.
    Chase, Jordan
    ADVANCES IN THERAPY, 2025, : 2385 - 2402
  • [8] Cost-consequence analysis evaluating multifaceted clinical pharmacist intervention targeting patient transitions of care from hospital to primary care
    Rasmussen, Maja Kjaer
    Ravn-Nielsen, Lene Vestergaard
    Duckert, Marie-Louise
    Lund, Mia Lolk
    Henriksen, Jolene Pilegaard
    Nielsen, Michelle Lyndgaard
    Eriksen, Christina Skovsende
    Buck, Thomas Croft
    Hansen, Morten Rix
    Pottegard, Anton
    Hallas, Jesper
    Kidholm, Kristian
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2019, 2 (02): : 123 - 130
  • [9] COST-CONSEQUENCE ANALYSIS OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB IN TREATMENT OF FIRST-LINE ADVANCED RENAL CELL CARCINOMA IN GERMANY: A PAYER PERSPECTIVE
    Gultyaev, D.
    Kaltenbach, E.
    Lothgren, M.
    Stiefel, J.
    Kisro, J.
    VALUE IN HEALTH, 2024, 27 (12) : S104 - S105
  • [10] Earlier ofatumumab treatment May reduce disease progression and relapses for patients with relapsing-remitting multiple sclerosis: results from a cost-consequence model
    Green, L.
    Montgomery, S.
    Durand, A.
    Loh, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 875 - 875
12345